Table 2.
Characteristics and outcome of COVID-19 patients receiving CCP.
| Pt.no. | Age (Years) | Sex | BMI | COVID-19 Vaccine/Doses | Days Since LastVaccine Dose to COVID-19 | Hospital Admission (m/d/y) |
VOC Lineage | COVID-19 Severity/Hospital Department |
Comorbidities/Complications | PaO2/FiO2 before CCP Transfusion |
Anti-SARS-CoV-2 IgG 1 |
Number of CCP Units Transfused/nAb Titer 2 | Days between Symptom Onset and CCP Transfusion |
Days between Last CCP Transfusion and VC | Previous/Concomitant Therapies |
Outcome 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 75 | M | 24 | No | - | 10/29/2021 | B.1.617.2 | Severe/RU | AF, hypertension | 140 | Negative | 3/320 | 14 | 11 | ST, HEP | Alive |
| 2 | 60 | M | 34 | Pfizer/2 | 160 | 11/16/2021 | B.1.617.2 | Severe/RU | Hypertension, diabetes, CT for thymoma | 156 | Negative | 3/160–320 | 10 | 10 | ST, HEP, REM | Alive |
| 3 | 52 | M | 33 | No | - | 11/18/2021 | B.1.617.2 | Severe/RICU | CRU, VABP, tracheostomy | 115 | Negative | 3/160 | 6 | 18 | ST, HEP, REM, mAbs 4 | Alive |
| 4 | 28 | F | 31 | No | - | 11/17/2021 | B.1.617.2 | Severe/RICU | Pituitary adenoma | 95 | Negative | 3/160–640 | 7 | 3 | ST, HEP | Alive |
| 5 | 50 | F | 29 | No | - | 09/21/2021 | B.1.617.2 | Severe/RU | Hypertension, tracheostomy | 94 | Negative | 1/160 | 9 | 7 | ST, HEP | Alive |
| 6 | 72 | M | 23 | Pfizer/3 | 98 | 01/08/2022 | B.1.617.2 | Severe/RU | NHL | 118 | Negative | 2/320 | 11 | NA | RTX, ST, HEP | Alive |
| 7 | 72 | M | 27 | Moderna/3 | 26 | 02/26/2022 | B.1.1.529 | Severe/RU | Diabetes, hypertension | 149 | Negative | 1/640 | 6 | 7 | ST, HEP | Alive |
| 8 | 78 | M | 35 | AZ/2 | 142 | 11/17/2021 | B.1.617.2 | Severe/RICU | Diabetes, hypertension, PC | 88 | Negative | 2/160 | 18 | NA | ST, HEP | Dead |
| 9 | 77 | M | 26 | No | - | 12/21/2021 | B.1.617.2 | Severe/RICU | CAD, hypertension, dyslipidemia, LC | 72 | Negative | 2/640 | 19 | NA | ST, HEP | Dead |
| 10 | 72 | M | 28 | No | - | 12/28/2021 | B.1.617.2 | Severe/RICU | Diabetes, MI, hypertension, FS | 144 | Negative | 2/160–640 | 9 | 4 | ST, HEP | Alive |
| 11 | 66 | M | 37 | Pfizer/2 | 176 | 12/30/2021 | B.1.617.2 | Severe/RICU | OSAS, diabetes, dyslipidemia, CAD | 91 | Negative | 1/640 | 11 | 10 | ST, HEP | Alive |
| 12 | 44 | M | 32 | No | - | 01/29/2022 | B.1.1.529 | Severe/ICU | Hypertension, VABP | 122 | Negative | 1/160 | 5 | 9 | ST, HEP | Alive |
| 13 | 81 | M | 28 | Moderna/1 | 2 | 12/23/2021 | B.1.617.2 | Severe/IMU | Hypertension, CPOA, SCI | 86 | Negative | 1/320 | 6 | NA | ST. HEP | Dead |
| 14 | 49 | M | 33 | No | - | 12/31/2021 | B.1.617.2 | Severe/IMU | None | 175 | Negative | 1/160 | 10 | 7 | ST, HEP | Alive |
| 15 | 72 | M | 23 | Pfizer/3 | 42 | 01/12/2022 | B.1.617.2 | Severe/IMU | CLL | 144 | Negative | 2/640 | 9 | NA | ST, HEP, REM, mAbs 4 | Alive |
| 16 | 61 | F | 21 | No | - | 01/24/2022 | B.1.1.529 | Severe/IMU | None | 117 | Negative | 1/160 | 6 | 4 | ST, HEP, REM | Alive |
| 17 | 54 | M | 24 | Pfizer/2 | 84 | 01/26/2022 | B.1.1.529 | Severe/IMU | None | 259 | Negative | 1/160 | 8 | 8 | ST, HEP | Alive |
| 18 | 50 | M | 26 | Moderna/2 | 22 | 01/22/2022 | B.1.1.529 | Severe/IMU | RA, 5 hypertension | 244 | Negative | 1/160 | 11 | 5 | ST, HEP, MTX | Alive |
| 19 | 74 | F | 22 | Moderna/3 | 153 | 03/03/2022 | B.1.1.529 | Severe/RICU | NHL | 81 | Negative | 2/320 | 1 | NA | ST, HEP, RTX | Alive |
| 20 | 76 | M | 25 | Pfizer/3 | 144 | 03/16/2022 | B.1.1.529 | Severe/RICU | CLL, CAD, hypertension | 147 | Negative | 2/640 | 3 | 3 | ST, HEP, RTX | Alive |
| 21 | 6 | M | 14 | No | - | 01/14/2022 | B.1.617.2 | Severe/ICU | PHLH | 230 | Negative | 2/320–640 | 15 | 21 | ST, REM, IVIG, ANA, RUX |
Alive |
Legend: M, male; F, female; NA, not available; AF, atrial fibrillation; RU, respiratory unit; RICU, respiratory intensive care unit; IMU, internal medicine unit; AZ, AstraZeneca; BMI, body mass index; ST, steroids, HEP, heparin; mAbs, anti-COVID-19 monoclonal antibodies; REM, remdesivir; CT, chemotherapy; CRU, colitis rectal ulcerous; VABP, ventilator-associated bacterial pneumonia; non-Hodgkin lymphoma; RTX, rituximab; PC, prostatic cancer; LC, lung cancer; FS, fungal septicemia; OSAS, obstructive sleep apnea syndrome; MI, myocardial ischemia; CAD, coronary artery disease; ICU, intensive care unit; CPOA, chronic peripheral obstructive arteriopathy, SCI, severe cognitive impairment; CLL, chronic lymphocytic leukemia; RA, rheumatoid arthritis; VC, viral clearance; PHLH, primary hemophagocytic lymphohistiocytosis; IVIG, intravenous aspecific immunoglobulin; ANA, anakinra; RUX, ruxolitinib; MTX, methotrexate. 1 Patients #3 and #5 were seronegative before mAb infusion. 2 nAb titered against VOC. 3 Twenty-eight days after hospitalization. 4 Casirivimab + imdevimab. 5 Under chronic steroid therapy.